The ACORE project: diagnostic contribution, prognosis, and pathophysiological aspects in arrhythmogenic cardiomyopathy
Background
- Identifying new diagnostic biomarkers is therefore a major challenge in this disease.
- Classified as a rare disease, Arrhythmogenic Cardiomyopathy (AC) is a hereditary cardiomyopathy responsible for serious ventricular rhythm disorders that can lead to sudden death or heart failure.
- This condition was first described in 1982 at the Pitié Salpêtrière Hospital, where more than 500 patients with this rare disease have been monitored since then.
- Despite recent advances in the diagnosis, genetics, and prognosis of this condition, many issues remain regarding diagnosis and prognostic stratification. It remains the most difficult hereditary cardiomyopathy to diagnose because there are no specific clinical or imaging criteria.
Project objectives
- Identify new biomarkers of inflammation in patients with arrhythmogenic cardiomyopathy or carriers of the responsible mutation(s).
- Determine the diagnostic value of newly identified biomarkers (circulating and imaging) in relation to current diagnostic criteria.
- Improving the diagnosis of arrhythmogenic cardiomyopathy to speed up patient care.
Patient benefits
Improving diagnosis for earlier management of Arrhythmogenic Cardiomyopathy
Duration of the study
- 10 years in total (5-year inclusion period + 5-year follow-up)
- 10 years in total (5-year inclusion period + 5-year follow-up)
Overall budget
€333,403
Project leaders
Prof. Estelle GANDJBAKHCH (Rhythmology Unit, INSERM 1166, IHU ICAN, La Pitié Salpêtrière Hospital)
Dr. Mikael LAREDO (Rhythmology Unit, IHU ICAN, La Pitié Salpêtrière Hospital)
Prof. Alban REDHEUIL (Cardiovascular and Thoracic Imaging, ICAN Institute, Pitié Salpêtrière Hospital)
Prof. Guy GOROCHOV (Immunology Department, La Pitié Salpêtrière Hospital)
